A. BBA, a Delaware limited partnership, is an investment adviser located in New York, New York and has been providing investment advisory services since January 2000. BBA serves as a discretionary investment adviser to certain private investment funds (each, a “Fund” or “Client” and collectively, the “Funds” or “Clients”), which are generally organized as limited partnerships. BBA’s founders and principal owners are Julian Baker and Felix Baker (the “Managing Members”). B. BBA generally has broad investment authority with respect to its Clients, subject to certain pre-agreed limitations applying on a portfolio-wide basis with respect to certain Clients and set forth in the applicable Client’s constituent documents (the “Investment Limits”). BBA’s Clients invest in public and private securities and related assets and revenue streams of life sciences and health care companies and cash management investments. These securities include, but are not limited to: (1) equity securities, including exchange-listed and over-the- counter securities; (2) warrants; (3) corporate debt securities, including convertible bonds; (4) options contracts on securities; (5) ETFs; and (6) money market funds. BBA focuses on public securities, but, from time to time, also recommends and makes investments on behalf of its Clients in private companies, life sciences and related health care intellectual property, royalty streams and other “non-public” investment opportunities. BBA provides investment advice with respect to other investment securities and instruments as is consistent

with each respective Client’s investment objective. C. BBA neither tailors its advisory services to the needs of individual investors in the Funds (“Investors”) nor accepts Investor-imposed investment restrictions other than the Investment Limits (which apply to all Investors in an applicable Fund). Though BBA utilizes a similar strategy for all of the Funds, it may tailor the advisory services it provides to Clients to the extent that certain investments cannot be held by certain of BBA’s Clients for legal, tax, portfolio concentration, or other investment based reasons. BBA has, however, in the past established, and may in the future establish additional, managed accounts or single investor funds for large or strategic investors. The advisory agreements for such managed accounts or funds will generally be subject to different terms than the Funds, including but not limited to, liquidity, investment objectives, guidelines and restrictions, fees and other terms. Only Baker Brothers Life Sciences, L.P., and its feeder Fund HCIF Offshore LP, are currently open to new Investors. D. BBA does not participate in wrap fee programs. E. As of December 31, 2023, the amount of Client assets managed by BBA (“RAUM”) was $21,976,239,930, all of which was managed by BBA on a discretionary basis. BBA subsequently returned a portion of the proceeds from the exit of a large Client investment to BBA's Investors. BBA’s RAUM as of February 1, 2024 was $15,628,258,358. BBA does not currently manage any Client assets on a non-discretionary basis.